Skip to main content

Table 3 Impact of HSV-2 seropositivity on HIV disease progression a

From: Herpes simplex virus type 2 and HIV disease progression: a systematic review of observational studies

Study

Population

N

HSV-2 Ascertainment

Results

Outcome

HSV2 positive

HSV2 negative

Difference

Effectb

Barnabas 2011

HIV seroconverters, Americas

87

Serology: Western Blot

Initiation of HAART

NR

NR

aHR = 1.3c, (95% CI = 0.5, 3.2)

↔

Crum-Cianflone 2006

USA

367

Serology: Focus

Time from HIV diagnosis to initiation of any ARTd

18 months

9 months

p = 0.10

↔

(range = 1,156)

(range = 1,96)

271

Proportion with CD4≤350 or 18% at 1 year of follow-upe

62/144 = 43%

66/127 = 52%

OR = 0.70, p = 0.15

↔

221

Proportion with CD4≤350 or 18% at 3 years of follow-upe

84/118 = 71%

75/103 = 73%

OR = 0.92, p = 0.88

↔

Roxby 2011

Postpartum women, Kenya

296

Serology: Focus

CD4≤200

50/254 = 20%

7/42 = 17%

aHR = 1.16f, (95% CI = 0.52,2.56), p = 0.72

↔

First OI

43/254 = 17%

2/42 = 5%

aHR = 3.83f, (95% CI = 0.93,15.83), p = 0.06

Faster?

Death

17/254 = 7%

2/42 = 5%

aHR = 1.33f, (95% CI = 0.32,6.05), p = 0.66

↔

Suligoi 2001

Italy

380

Serology: Pockit

AIDS

NR

NR

HR = 1.68, (95% CI = 1.19,2.37), Adjustedg HR = 1.13, (95% CI = 0.76, 1.70)

Faster?

  1. aCI = confidence interval, HAART = highly active antiretroviral therapy, HR = hazard ratio, NR = not reported, OI = Opportunistic infection, OR = odds ratio.
  2. bArrows show directions of association with HSV-2; ‘?’ denotes borderline statistical significance or clinically significant differences not meeting statistical significance.
  3. cAdjusted for adenovirus 5 immunity, region, circumcision status, age, race, HLA group, trial intervention assignment (vaccine / placebo).
  4. dIncludes any ART (monotherapy, non-HAART combination therapy and HAART).
  5. eDefined as CD4 count <350 cells/mm3 or 18%.
  6. fAdjusted for baseline CD4 count.
  7. gAdjusted for age at HIV seroconversion, exposure category, sex.